

Brian K Link

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40285/publications.pdf>

Version: 2024-02-01

256
papers

14,769
citations

23544

58
h-index

21521

114
g-index

259
all docs

259
docs citations

259
times ranked

15989
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
2	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084
3	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	3.3	853
4	Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 3135-3143.	0.8	653
5	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
6	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	6.3	517
7	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	0.8	364
8	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
9	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	0.8	263
10	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
11	Improved Survival of Follicular Lymphoma Patients in the United States. <i>Journal of Clinical Oncology</i> , 2005, 23, 5019-5026.	0.8	249
12	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	0.6	247
13	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. <i>Blood</i> , 2006, 108, 2648-2654.	0.6	215
14	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
15	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
16	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
17	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
18	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	0.6	161

#	ARTICLE	IF	CITATIONS
19	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	0.8	154
20	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
21	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	3.2	149
22	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
23	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	1.2	145
24	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenström's Macroglobulinemia. <i>Journal of Immunotherapy</i> , 2001, 24, 272-279.	1.2	144
25	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	0.8	144
26	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
27	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	0.6	136
28	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
29	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012, 119, 3698-3704.	0.6	125
30	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
31	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. <i>Blood</i> , 2011, 118, 3347-3349.	0.6	117
32	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
33	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
34	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , 2016, 128, 1234-1245.	0.6	105
35	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
36	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97

#	ARTICLE	IF	CITATIONS
37	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
38	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
39	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
40	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	0.8	93
41	Delivering adjuvant chemotherapy to women with early-stage breast carcinoma. <i>Cancer</i> , 2001, 92, 1354-1367.	2.0	91
42	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. <i>Journal of Leukocyte Biology</i> , 2005, 77, 378-387.	1.5	90
43	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 975-983.	0.6	90
44	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
45	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	0.6	82
46	Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. <i>Clinical Cancer Research</i> , 2019, 25, 2996-3005.	3.2	80
47	Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results. <i>Clinical Cancer Research</i> , 2009, 15, 7375-7380.	3.2	79
48	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	0.8	75
49	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
50	Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. <i>EMBO Journal</i> , 2018, 37, .	3.5	73
51	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101. <i>Journal of Clinical Oncology</i> , 2010, 28, 4500-4506.	0.8	71
52	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
53	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
54	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	0.6	67

#	ARTICLE	IF	CITATIONS
55	Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: A series of 10 adult and pediatric patients and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 739-748.	0.6	66
56	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. <i>Blood</i> , 2012, 119, 469-475.	0.6	66
57	Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	64
58	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	3.2	64
59	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 1395-1403.	3.2	61
60	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	0.6	58
61	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
62	Humanization and characterization of the anti-HLA-DR antibody 1D10. <i>International Journal of Cancer</i> , 2001, 93, 556-565.	2.3	57
63	Primary Breast Lymphoma in the United States: 1975-2013. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	57
64	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
65	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55
66	Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin's Lymphoma (United States). <i>Cancer Causes and Control</i> , 2006, 17, 647-654.	0.8	54
67	Cyclophosphamide, Vincristine, and Prednisone Followed by Tositumomab and Iodine-131 Tositumomab in Patients With Untreated Low-Grade Follicular Lymphoma: Eight-Year Follow-Up of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3035-3041.	0.8	54
68	Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. <i>Blood</i> , 2016, 127, 200-207.	0.6	52
69	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
70	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	1.2	51
71	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	0.6	50
72	Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. <i>Leukemia and Lymphoma</i> , 2011, 52, 994-1002.	0.6	50

#	ARTICLE	IF	CITATIONS
73	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	1.4	50
74	Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015, 170, 85-95.	1.2	50
75	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50
76	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
77	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
78	Factors Associated with Early Termination of CHOP Therapy and the Impact on Survival among Patients with Chemosensitive Intermediate-Grade Non-Hodgkin's Lymphoma. <i>Cancer Control</i> , 2003, 10, 396-403.	0.7	44
79	Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	1.2	44
80	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
81	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	0.8	42
82	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
83	Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States. <i>Cancer</i> , 2012, 118, 4842-4850.	2.0	40
84	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	0.6	37
85	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
86	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
87	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	2.0	36
88	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.4	34
89	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	2.0	33
90	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. <i>Cancer</i> , 2014, 120, 1830-1837.	2.0	33

#	ARTICLE	IF	CITATIONS
91	Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <i>American Journal of Hematology</i> , 2014, 89, 757-765.	2.0	32
92	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγR1a Patients with Previously Treated Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 42-48.	0.6	29
93	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
94	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
95	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	0.6	28
96	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
97	Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. , 1998, 77, 251-256.		27
98	Maintenance rituximab or observation after frontline treatment with bendamustine+rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
99	Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	2.8	27
100	Phase II Trial of Remitogen, (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 188-190.	2.1	26
101	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	2.0	26
102	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
103	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
104	Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. <i>Leukemia and Lymphoma</i> , 2015, 56, 65-71.	0.6	24
105	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
106	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
107	Recommendations for Clinical Trial Development in Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw255.	3.0	23
108	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	2.0	23

#	ARTICLE	IF	CITATIONS
109	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	0.6	22
110	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	2.0	22
111	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
112	18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of "indeterminate" reports. <i>Leukemia and Lymphoma</i> , 2010, 51, 439-446.	0.6	21
113	Population-Based Exploration of Academic Achievement Outcomes in Pediatric Acute Lymphoblastic Leukemia Survivors. <i>Journal of Pediatric Psychology</i> , 2012, 37, 458-466.	1.1	21
114	A systematic review of validated methods for identifying lymphoma using administrative data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 203-212.	0.9	21
115	Monoclonal antibody therapy of B cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 375-385.	1.4	20
116	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
117	Clinical Protocol: Phase I Study of an Adenovirus/Prostate-Specific Antigen Vaccine in Men with Metastatic Prostate Cancer. <i>Human Gene Therapy</i> , 2006, 17, 220-229.	1.4	19
118	Health-related quality of life in patients with cutaneous T-cell lymphoma?. <i>International Journal of Dermatology</i> , 2018, 57, 1314-1319.	0.5	19
119	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	2.0	19
120	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	2.0	18
121	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 417-422.	2.0	18
122	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
123	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
124	99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2004, 25, 839-843.	0.5	16
125	Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. <i>Leukemia and Lymphoma</i> , 2006, 47, 657-663.	0.6	16
126	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	1.4	16

#	ARTICLE	IF	CITATIONS
127	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	2.0	16
128	Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation. <i>Cancer</i> , 2017, 123, 4168-4177.	2.0	16
129	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
130	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
131	Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2870-2875.	0.6	15
132	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
133	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15
134	Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E62-E64.	2.0	15
135	Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. <i>Leukemia and Lymphoma</i> , 1998, 31, 237-249.	0.6	14
136	Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. <i>Leukemia and Lymphoma</i> , 2018, 59, 643-649.	0.6	14
137	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. <i>British Journal of Haematology</i> , 2012, 159, n/a-n/a.	1.2	13
138	Papular mycosis fungoides: report of two patients, literature review, and conceptual reappraisal. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 714-719.	0.7	13
139	Mapping of the IRF8 Gene Identifies a 3' UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 461-466.	1.1	13
140	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	1.2	13
141	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	0.8	13
142	Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. <i>Journal of Clinical Oncology</i> , 2016, 34, 7516-7516.	0.8	13
143	Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. <i>PLoS ONE</i> , 2013, 8, e76889.	1.1	13
144	Influences on Oncologists' Adoption of New Agents in Adjuvant Chemotherapy of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 954-959.	0.8	12

#	ARTICLE	IF	CITATIONS
145	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 954-961.	3.2	12
146	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
147	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	0.6	11
148	Novel treatment approaches and future perspectives in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882051.	1.1	11
149	Follicular lymphomatoid papulosis with follicular mucinosis: a clinicopathologic study of 3 cases with literature review and conceptual reappraisal. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 360-366.	0.7	10
150	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. <i>Blood</i> , 2011, 118, 97-97.	0.6	10
151	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
152	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
153	Antibody Therapy of Lymphoma. <i>Advances in Pharmacology</i> , 2004, 51, 229-253.	1.2	8
154	Effect of Clinical Characteristics on Neutropenia-Related Inpatient Costs Among Newly Diagnosed Non-Hodgkin's Lymphoma Cases During First-Course Chemotherapy. <i>Pharmacotherapy</i> , 2005, 25, 668-675.	1.2	8
155	Monoclonal Antibodies in Lymphoma: The First Decade. <i>Seminars in Hematology</i> , 2008, 45, 71-74.	1.8	8
156	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	2.0	8
157	Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2014, 124, 1664-1664.	0.6	8
158	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	0.6	8
159	Post-treatment surveillance of patients with lymphoma treated with curative intent. <i>Seminars in Oncology</i> , 2003, 30, 375-381.	0.8	7
160	Optic neuropathy due to anaplastic large cell lymphoma. <i>Seminars in Ophthalmology</i> , 2004, 19, 81-87.	0.8	7
161	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	0.6	7
162	Single-cell analysis of SÅzary syndrome reveals novel markers and shifting gene profiles associated with treatment. <i>Blood Advances</i> , 2023, 7, 321-335.	2.5	7

#	ARTICLE	IF	CITATIONS
163	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). <i>HemaSphere</i> , 2022, 6, e745.	1.2	7
164	Transformation of follicular lymphoma – Why does it happen and can it be prevented?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 49-56.	0.7	6
165	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
166	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
167	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	0.6	6
168	Updated Metaanalysis Finds That Interferon- γ Improves Progression-Free and Overall Survival in Low-Grade Non-Hodgkin's Lymphoma When Administered with Chemotherapy That Contains Anthracyclines or Mitoxantrone. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 82-84.	2.1	5
169	Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. <i>Advances in Hematology</i> , 2011, 2011, 1-7.	0.6	5
170	Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 95-107.	0.6	5
171	Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2566-2567.	0.8	5
172	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
173	Primary diffuse large B cell lymphoma of the vulva – Two new cases of a rare entity and review of the literature. <i>JAAD Case Reports</i> , 2018, 4, 962-967.	0.4	5
174	Pre-treatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
175	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	1.5	5
176	CD20+ cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature. <i>JAAD Case Reports</i> , 2020, 6, 308-310.	0.4	5
177	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	0.6	5
178	Risk Factors for Early Transformation of Follicular Lymphoma (FL): Report From the National LymphoCare Study (NLCS).. <i>Blood</i> , 2009, 114, 2698-2698.	0.6	5
179	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 510-510.	0.6	5
180	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5

#	ARTICLE	IF	CITATIONS
181	Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e11-e25.	0.2	4
182	Repeatability and Reproducibility of In Vivo Cone Density Measurements in the Adult Zebrafish Retina. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1074, 151-156.	0.8	4
183	Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017. <i>RMD Open</i> , 2020, 6, e001241.	1.8	4
184	Foreseeing what is to happen in DLBCL. <i>Blood</i> , 2020, 135, 2014-2015.	0.6	4
185	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
186	Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS). <i>Blood</i> , 2012, 120, 3708-3708.	0.6	4
187	Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2681-2681.	0.6	4
188	Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S180-S186.	1.4	3
189	Measuring Granulocyte and Monocyte Accumulation at Malignant Lymphoma Sites. <i>Journal of Clinical Oncology</i> , 2009, 27, 154-155.	0.8	3
190	Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 443-455.	1.1	3
191	Reply to V. Pitini et al and L.J. Costa. <i>Journal of Clinical Oncology</i> , 2015, 33, 1625-1626.	0.8	3
192	Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 703-712.	0.7	3
193	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	0.6	3
194	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
195	A phase III trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 424-428.	2.3	2
196	The mysteries of mantle cell lymphoma—do PET scans provide a clue?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1662-1663.	0.6	2
197	Chemo-immunotherapy dosing in older patients with diffuse large B-cell lymphoma: is this how we should treat our parents?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1435-1436.	0.6	2
198	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	0.4	2
200	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
201	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	0.6	2
202	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	0.6	2
203	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). <i>Blood</i> , 2021, 138, 1349-1349.	0.6	2
204	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	2.5	2
205	Imaging Guiding Therapy Development in Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 443-445.	2.3	1
206	Early Relapse in Follicular Lymphoma: High Risks and High Stakes. <i>Journal of Oncology Practice</i> , 2017, 13, 810-811.	2.5	1
207	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
208	Incidence of Febrile Neutropenia Is Low and Unrelated to Day 1 Neutrophil Count in Hodgkin's Lymphoma Treated with ABVD. <i>Blood</i> , 2004, 104, 4590-4590.	0.6	1
209	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	0.6	1
210	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 4245-4245.	0.6	1
211	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
212	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
213	Paraneoplastic erythema annulare centrifugum associated with mycosis fungoides. <i>JAAD Case Reports</i> , 2021, 17, 65-68.	0.4	1
214	In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines. <i>Blood</i> , 2005, 106, 4826-4826.	0.6	1
215	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ’) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	0.6	1
216	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
218	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
219	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
220	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
221	Cell migration. , 0, , 59-74.		0
222	Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 219-224.	1.2	0
223	Biosimilars: when a negative study can be positive. <i>Lancet Haematology</i> , the, 2018, 5, e500-e501.	2.2	0
224	Immunologic dysfunction and Hodgkin lymphoma: Insight to better therapy?. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 780-781.	1.5	0
225	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
226	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
227	Correlates of Treatment Intensity for Initial Management of Follicular Lymphoma (FL) in the United States: Report from the National Lymphocare Study (NLCS).. <i>Blood</i> , 2007, 110, 2612-2612.	0.6	0
228	Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study. <i>Blood</i> , 2012, 120, 3702-3702.	0.6	0
229	Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms. <i>Blood</i> , 2012, 120, 4884-4884.	0.6	0
230	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
231	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
232	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
233	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	0.6	0
234	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Shroom3, a novel GWAS renal candidate, is essential for glomerular barrier function. FASEB Journal, 2013, 27, 955.6.	0.2	0
236	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	0.6	0
237	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	0.6	0
238	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. Blood, 2013, 122, 4288-4288.	0.6	0
239	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
240	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. Blood, 2013, 122, 3058-3058.	0.6	0
241	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	0.6	0
242	Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors. Blood, 2018, 132, 4791-4791.	0.6	0
243	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	0.6	0
244	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	0.6	0
245	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. Blood, 2021, 138, 2425-2425.	0.6	0
246	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. Blood, 2021, 138, 338-338.	0.6	0
247	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. Blood, 2021, 138, 808-808.	0.6	0
248	Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. Blood, 2021, 138, 453-453.	0.6	0
249	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	0.6	0
250	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	0.6	0
251	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	0.6	0
252	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	0.6	0

#	ARTICLE	IF	CITATIONS
253	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	0.6	0
254	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. Blood, 2020, 136, 7-8.	0.6	0
255	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. Blood, 2020, 136, 15-16.	0.6	0
256	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. JCO Oncology Practice, 0, , .	1.4	0